Company Description
Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States.
The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection.
It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV.
The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection.
It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC.
The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014.
Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
| Country | United States |
| IPO Date | Dec 17, 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Jason A. Okazaki |
Contact Details
Address: 331 Oyster Point Boulevard South San Francisco, California United States | |
| Website | https://www.assemblybio.com |
Stock Details
| Ticker Symbol | ASMB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001426800 |
| CUSIP Number | 045396108 |
| ISIN Number | US0453962070 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Jason A. Okazaki | Chief Executive Officer, President & Director |
| Amy Figueroa C.F.A. | Investor Relations Consultant |
| Dr. Adam Zlotnick | Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board |
| Dr. Anuj Gaggar M.D., Ph.D. | Chief Medical Officer |
| Dr. Nicole S. White Ph.D. | Chief Manufacturing Officer |
| Dr. Uri A. Lopatin M.D. | Co-Founder and Clinical & Scientific Advisor |
| Dr. William E. Delaney IV, Ph.D. | Chief Scientific Officer |
| Jeanette M Bjorkquist | Executive Director of Accounting & Treasury |
| Jennifer A. Troia MHROD, SHRM-SCP, SPHR | Chief Human Resources Officer |
| Thomas E. Rollins | Executive Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 03, 2025 | 8-K | Current Report |
| Dec 31, 2024 | 4 | Filing |
| Dec 26, 2024 | 8-K | Current Report |
| Dec 23, 2024 | 4 | Filing |
| Dec 23, 2024 | SCHEDULE 13D/A | [Amend] Filing |
| Dec 23, 2024 | SCHEDULE 13G/A | [Amend] Filing |
| Dec 23, 2024 | SCHEDULE 13G | Filing |
| Dec 19, 2024 | 8-K | Current Report |
| Dec 13, 2024 | 8-K | Current Report |
| Nov 26, 2024 | 4 | Filing |